Valuation models
price $359.41 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused103.76 – 156.07125.82186% overvaluedDCF · Perpetuity growth · 10y120.74 – 175.74144.02150% overvaluedDCF · EBITDA exit · 5y410.81 – 452.04430.8617% undervaluedDCF · EBITDA exit · 10y344.01 – 411.56376.164% undervaluedEV/EBITDA · peers51.58 – 89.3053.13576% overvaluedEV/Revenue · peers225.04 – 255.03234.8553% overvaluedEarnings power value25.97 – 54.2537.85850% overvaluedWall St. consensus target—330.009% aboveCost of capital (WACC)—9.38%—
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. How the headline model is chosen. The price is 186% above the model value: the models see only the filed business, and a company priced on businesses with no revenue line yet is better taken apart, as Tesla is.
Model value · DCF · Perpetuity growth · 5y
125.82
Charles River Laboratories closed at $359.41 — overvalued by 186% vs model.
103.76the model's range156.07
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
37.85 – 430.86
Wall St. target
330.00 9% above
Above model, 1y
30 of 30 days
How it is valued
Valued asMature & Stable
Revenue declining (~-1% recent)Currently unprofitableHighly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.